Predictive Drug Discovery Services
Therapeutic Areas: Gastrointestinal

Gastrointestinal (GI) diseases refer to disorders of the esophagus, stomach, small intestine, large intestine and rectrum, an the accessory organs of digestions including the liver, gallbladder and pancreas. Currently, strong research interest for drug development is focused on various Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn’s. Autoimmune diseases such as Celiac diseases is also of intense interest.




At REPROCELL’s Centre for Predictive Drug Discovery (formerly Biopta), contract research services employing live human GI tract tissues can be used for investigating drug effects on gut motility, permeability, inflammation and ion channel function. Our staff have extensive experience with efficacy, contractility, safety, ex vivo cultures and ADME assays using GI tract tissue. We are also currently developing iPSC-derived (bioengineered) Predictive Drug Discovery to mimic mucosal membranes for unique applications such as in drug transport. Human GI tissue specimens such as colon cancer, stomach cancer, IBD and blood or plasma from such patients are also available from BioServe tissue resources.